ABVC BioPharma

As of December 31, 2025, cash and cash equivalents were about 0.68 million dollars, operating cash outflow was 2.99 million dollars, and the working capital deficit was 3.66 million dollars. The auditor cited substantial doubt about the company’s ability to continue as a going concern.

While the company regained Nasdaq compliance in May 2025, sustainability depends on external financing and milestone cash that is uncertain or being returned. Convertible notes and related‑party transactions add complexity.